Volume | 40,003,810 |
|
|||||
News | - | ||||||
Day High | 0.1735 | Low High |
|||||
Day Low | 0.1522 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.1586 | 0.1522 | 0.1735 | 0.168 | 0.1799 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
26,005 | 40,003,810 | $ 0.1609869 | $ 6,440,089 | - | 0.0512 - 1.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:57 | 5 | $ 0.1703 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.63M | 50.76M | - | 9.76M | -41.3M | -0.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.15 | 0.254 | 0.1421 | 0.1758066 | 190,727,594 | 0.0201 | 13.40% |
1 Month | 0.0728 | 0.254 | 0.0653 | 0.1405773 | 89,694,517 | 0.0973 | 133.65% |
3 Months | 0.1066 | 0.254 | 0.0512 | 0.116773 | 62,065,104 | 0.0635 | 59.57% |
6 Months | 0.3215 | 0.5144 | 0.0512 | 0.125201 | 33,020,317 | -0.1514 | -47.09% |
1 Year | 0.56 | 1.22 | 0.0512 | 0.1607475 | 17,979,210 | -0.3899 | -69.63% |
3 Years | 108.00 | 228.00 | 0.0512 | 22.49 | 9,084,139 | -107.83 | -99.84% |
5 Years | 1,207.50 | 1,391.25 | 0.0512 | 72.23 | 9,615,702 | -1,207.33 | -99.99% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |